Printer Friendly

MEDIMMUNE AND CYANAMID TO ENTER FOUR DRUG, $30 MILLION STRATEGIC ALLIANCE

 GAITHERSBURG, Md., July 14 /PRNewswire/ -- MedImmune, Inc. (NASDAQ: MEDI) today announced it signed a letter of intent with American Cyanamid Company (NYSE: ACY) to form an alliance in the United States for the development and marketing of three generations of products for respiratory syncytial virus (RSV) and for the marketing of a new product, Zosyn(TM), developed by Cyanamid and currently under review for marketing approval by the United States Food and Drug Administration. The alliance involves Cyanamid and its Lederle Laboratories and Lederle Praxis Biologicals divisions. The terms of the letter of intent have been approved by the boards of directors of both companies, but are subject to negotiation and execution of definitive agreements.
 Under the terms of the agreement, MedImmune and Cyanamid would collaborate on the following products for RSV: (i) Respivir(TM), a polyclonal antibody product developed by MedImmune and currently under review for marketing approval by the FDA, (ii) a second generation monoclonal antibody product being developed by MedImmune, and (iii) a vaccine being developed by Cyanamid's Lederle Praxis Biologicals division. The fourth product included in the agreement would be Zosyn(TM), an anti-infective developed by Cyanamid's Lederle Laboratories Division for hospital use to treat a broad spectrum of infectious pathogens. Cyanamid is currently expecting marketing approval of Zosyn(TM) later this year. In addition to co-promoting these four products, MedImmune would receive up to $30 million in funding from Cyanamid.
 "As a leading company in the U.S. pediatric pharmaceutical market, Lederle is an ideal partner to help MedImmune maximize the value of Respivir," commented Wayne T. Hockmeyer, Ph.D., chairman and chief executive officer. "In addition, we expect this alliance to enhance our market presence in the near term through the co-promotion of Zosyn and in the long term through the addition of an RSV vaccine program. The cash we will receive from Cyanamid provides capital for Respivir inventory and market development and for development of future RSV products."
 The proposed alliance involves co-promoting Respivir in the U.S. and co-developing and co-promoting the second generation monoclonal antibody product for RSV in the U.S. In addition, MedImmune would have the option to co-develop and co-promote Lederle Praxis Biologicals' RSV vaccine which is in clinical trials. MedImmune would detail the RSV products directly to hospitals through its own sales force, while Lederle's pediatric office and hospital sales forces of more than 1,000 representatives would detail to pediatricians and hospitals. The companies intend to share development costs and profits on the RSV products. The proposed collaboration also includes co-promotion and profit sharing on Lederle's Zosyn which MedImmune would detail through its hospital sales force. MedImmune would book sales for Respivir and the RSV monoclonal antibody product and Cyanamid would book sales for Zosyn and the RSV vaccine.
 RSV is the leading cause of pneumonia and bronchiolities in infants. Severe RSV disease occurs most frequently in children under the age of two. More than 91,000 hospitalizations and 4,500 deaths occur each year in the U.S. as a result of RSV infection in children. Children with pre-existing conditions, including lung or heart disease, prematurity or immunosuppression, are at significantly increased risk for severe disease and death from RSV. No product is currently licensed for prevention of RSV infection in the United States.
 Zosyn is a combination of piperacillin, a semisynthetic penicillin, and tazobactam, a beta-lactamase inhibitor, developed by Lederle as a broad spectrum anti-infective. Zosyn is already available overseas and is currently awaiting marketing approval in the United States. The product targets the more than $2 billion intravenous antibiotic market in the U.S. Zosyn has potent activity against aerobic and anaerobic gram positive and gram negative organisms.
 MedImmune would begin to co-promote Zosyn in the hospital immediately upon approval and expand its efforts over time.
 Cyanamid, through its Lederle Laboratories and Lederle-Praxis Biologicals divisions, is a leader in the United States in the research, development and marketing of pharmaceuticals and vaccines to the pediatrician. In addition, through Lederle-Praxis Biologicals, Cyanamid has an almost ten year commitment to the development of a vaccine for RSV disease.
 Dr. Hockmeyer added that "We believe Cyanamid's strength in the U.S. market and the strategic fit between our companies make this alliance an excellent opportunity for MedImmune. We believe the strength of Lederle's sales forces can increase Respivir's market penetration, especially through access to the office-based pediatrician, and thereby increase the potential of Respivir for MedImmune. This marketing alliance demonstrates our commitment to building our hospital sales force and to the long term opportunity we see in the development of products for RSV disease. We are now evaluating the best strategy for maximizing the value of Respivir outside the United States and expect to finalize our strategy later this year."
 MedImmune, Inc. was formed in 1988 to develop, manufacture and market therapeutics and vaccines for the treatment and prevention of certain infectious diseases and cancers. MedImmune's corporate headquarters are in Gaithersburg, Md.
 Cyanamid is a research-based life sciences and chemical company which discovers and develops medical, agricultural and chemical products and manufactures and markets them in more than 135 countries.
 -0- 7/14/93
 /CONTACT: David M. Mott, vice president - business development and planning of MedImmune, Inc., 301-417-0770, or Anthony J. Russo, Ph.D., of Noonan-Russo Communications, Inc., 212-979-9180, for MedImmune, Inc./
 (MEDI ACY)


CO: MedImmune, Inc., Cyanamid Company ST: Maryland IN: MTC SU: JVT

LD -- NY004 -- 1254 07/14/93 09:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 14, 1993
Words:908
Previous Article:'FRIENDS TOGETHER' BRINGS HOPE TO CHILDREN IN NEED
Next Article:MARTIN MARIETTA UPPER STAGE TO LAUNCH PAYLOAD FROM SHUTTLE
Topics:


Related Articles
AMERICAN CYANAMID, HOUGHTEN PHARMACEUTICALS SIGN RESEARCH COLLABORATION AGREEMENT
MEDIMMUNE AND CYANAMID SIGN FOUR DRUG, $30 MILLION STRATEGIC ALLIANCE; MEDIMMUNE AND CYANAMID TO BEGIN SELLING ZOSYN TODAY
IMMUNEX REGAINS RIGHTS TO PIXYKINE; CYANAMID TO DEVELOP PRODUCT FOR OVERSEAS MARKETS
HAUSER ANNOUNCES PACLITAXEL RESEARCH & COMMERCIALIZATION AGREEMENTS
MEDIMMUNE FORMS ALLIANCE WITH BAXTER TO DEVELOP AND MARKET RESPIGAM OUTSIDE NORTH AMERICA
MEDIMMUNE ANNOUNCES NEW SUPPLY AGREEMENT FOR RESPIGAM RAW MATERIALS
MedImmune and Abbott Laboratories Sign Global Alliance to Market MEDI-493
American Cyanamid and Hyseq Sign Broad Scale Gene Product Agreement.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters